{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-335101","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2026-08-05T20:10:16+00:00","discovered_at":"2026-08-05T20:11:00.233951+00:00","generated_at":"2026-08-05T20:11:34.421916+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Enliven Therapeutics Q2 net loss $32.5M; positive Phase 1 data for ELVN-001 in CML; cash $895M into 2030","bullets":["Net loss of $32.5M for Q2 2026 vs $25.3M in Q2 2025; R&D expenses $29.0M.","Cash, cash equivalents and marketable securities of $895.2M as of June 30, 2026, expected to fund operations into 2030.","ELVN-001 Phase 1 data: 61% overall MMR, 48% MMR by 24 weeks in 80mg QD cohort; favorable safety profile.","FDA alignment on Phase 3 ENABLE-2 trial design; 80mg QD selected as recommended dose; Fast Track Designation granted.","Expect to initiate ENABLE-2 Phase 3 trial in H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-335101","json":"https://secwatch.observer/filing/0001193125-26-335101.json","markdown":"https://secwatch.observer/filing/0001193125-26-335101.md","text":"https://secwatch.observer/filing/0001193125-26-335101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312526335101/0001193125-26-335101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312526335101/elvn-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:11:34.421916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}